To include your compound in the COVID-19 Resource Center, submit it here.

BridgeBio gets rights to Novartis' FGFR kinase inhibitor

Novartis AG (NYSE:NVS; SIX:NOVN) granted BridgeBio Pharma LLC (Palo Alto, Calif.) rights to infigratinib (BGJ398), a fibroblast

Read the full 177 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE